BMS’ Opdivo cleared for monthly use by Selina McKee | Mar 7, 2018 | News | 0 US regulators have approved a label update to Bristol-Myers Squibb’s Opdivo, waving through a new dosing option for the immunotherapy of every four weeks. Read More
Janssen seeks to expand use of multiple myeloma drug by Selina McKee | Aug 19, 2016 | News | 0 Janssen Biotech is seeking to expand the scope of Darzalex as a second-line combination treatment for multiple myeloma. Read More